Summary of Study ST001212

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000823. The data can be accessed directly via it's Project DOI: 10.21228/M89D5Q This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Study ID	ST001212
Study Title	Fish-oil supplementation in pregnancy, child metabolomics and asthma risk
Study Summary	We investigated potential metabolic mechanisms using untargeted liquid chromatography-mass spectrometry-based metabolomics on 577 plasma samples collected at age 6 months in the offspring of mothers participating in the n-3 LCPUFA randomized controlled trial. First, associations between the n-3 LCPUFA supplementation groups and child metabolite levels were investigated using univariate regression models and data-driven partial least square discriminant analyses (PLS-DA). Second, we analyzed the association between the n-3 LCPUFA metabolomic profile and asthma development using Cox-regression. Third, we conducted mediation analyses to investigate whether the protective effect of n-3 LCPUFA on asthma was mediated via the metabolome
Institute	University of Copenhagen
Department	Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital
Last Name	Rago
First Name	Daniela
Address	Ledreborg Alle 34, DK-2820 Gentofte; Denmark
Email	daniela.rago@dbac.dk
Phone	(+45) 39777360
Submit Date	2019-07-10
Analysis Type Detail	LC-MS
Release Date	2019-09-23
Release Version	1

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR001313
Treatment Summary:	The pregnant women were enrolled in a double-blind, randomized controlled trial (DB-RCT)3. At enrollment during pregnancy week 22-26, the women were randomly assigned in a 1:1 ratio to receive 2.4 g per day of n−3 long-chain polyunsaturated fatty acids (LCPUFAs) in triacylglycerol form from fish oil capsules containing 55% eicosapentaenoic acid (20:5n–3, EPA) and 37% docosahexaenoic acid (22:6n–3, DHA (Incromega TG33/22, Croda, Health Care) or placebo in the form of lookalike olive oil capsules, containing 72% n–9 oleic acid and 12% n−6 linoleic acid (Pharma-Tech A/S). The women continued taking the daily supplement until 1 week after delivery, where they visited the research unit with their child. A subgroup of the pregnant women (n=623) also participated in another DB-RCT with a nested 2x2 factorial design in which they were assigned to 2400 IU of vitamin D per day or placebo from pregnancy week 22-26 till 1 week postpartum on top of the recommended pregnancy supplement of 400 IU/d; i.e. the women received 2800 vs. 400 IU/d of vitamin D, which did not significantly affect the offspring’s risk of developing asthma

Treatment ID:

TR001313

Treatment Summary:

The pregnant women were enrolled in a double-blind, randomized controlled trial (DB-RCT)3. At enrollment during pregnancy week 22-26, the women were randomly assigned in a 1:1 ratio to receive 2.4 g per day of n−3 long-chain polyunsaturated fatty acids (LCPUFAs) in triacylglycerol form from fish oil capsules containing 55% eicosapentaenoic acid (20:5n–3, EPA) and 37% docosahexaenoic acid (22:6n–3, DHA (Incromega TG33/22, Croda, Health Care) or placebo in the form of lookalike olive oil capsules, containing 72% n–9 oleic acid and 12% n−6 linoleic acid (Pharma-Tech A/S). The women continued taking the daily supplement until 1 week after delivery, where they visited the research unit with their child. A subgroup of the pregnant women (n=623) also participated in another DB-RCT with a nested 2x2 factorial design in which they were assigned to 2400 IU of vitamin D per day or placebo from pregnancy week 22-26 till 1 week postpartum on top of the recommended pregnancy supplement of 400 IU/d; i.e. the women received 2800 vs. 400 IU/d of vitamin D, which did not significantly affect the offspring’s risk of developing asthma